Literature DB >> 12094756

Proportional hazards models with random effects to examine centre effects in multicentre cancer clinical trials.

T Yamaguchi1, Y Ohashi, Y Matsuyama.   

Abstract

In randomized clinical trials comparing treatment effects on diseases such as cancer, a multicentre trial is usually conducted to accrue the required number of patients within a reasonable period of time. The fundamental point of conducting a multicentre trial is that all participating investigators must agree to follow the common study protocol. However, even with every attempt having been made to standardize the methods for diagnosing severity of disease and evaluating response to treatment, for example, they might be applied differently at different centres, and these may vary from comprehensive cancer centres to university hospitals to community hospitals. Therefore, in multicentre trials there is likely to be some degree of variation (heterogeneity) among centres in both the baseline risks and the treatment effects. While we estimate the overall treatment effect using a summary measure such as hazard ratio and usually interpret it as an average treatment effect over the centre, it is necessary to examine the homogeneity of the observed treatment effects across centres, that is, treatment-by-centre interaction. If the data are reasonably consistent with homogeneity of the observed treatment effects across centres, a single summary measure is adequate to describe the trial results and those results will contribute to the scientific generalization, the process of synthesizing knowledge from observations. On the other hand, if heterogeneity of treatment effects is found, we should carefully interpret the trial results and investigate the reason why the variation is seen. In the analyses of multicentre trials, a random effects approach is often used to model the centre effects. In this article, we focus on the proportional hazards models with random effects to examine centre variation in the treatment effects as well as the baseline risks, and review the parameter estimation procedures, frequentist approach-penalized maximum likelihood method--and Bayesian approach--Gibbs sampling method. We also briefly review the models for bivariate responses. We present a few real data examples from the biometrical literature to highlight the issues.

Entities:  

Mesh:

Year:  2002        PMID: 12094756     DOI: 10.1191/0962280202sm284ra

Source DB:  PubMed          Journal:  Stat Methods Med Res        ISSN: 0962-2802            Impact factor:   3.021


  8 in total

1.  Validation of prognostic indices using the frailty model.

Authors:  C Legrand; L Duchateau; P Janssen; V Ducrocq; R Sylvester
Journal:  Lifetime Data Anal       Date:  2008-07-11       Impact factor: 1.588

2.  MULTI-CENTER CLINICAL TRIALS: RANDOMIZATION AND ANCILLARY STATISTICS.

Authors:  L U Zheng; Marvin Zelen
Journal:  Ann Appl Stat       Date:  2008-07-03       Impact factor: 2.083

3.  VERTICOX: Vertically Distributed Cox Proportional Hazards Model Using the Alternating Direction Method of Multipliers.

Authors:  Wenrui Dai; Xiaoqian Jiang; Luca Bonomi; Yong Li; Hongkai Xiong; Lucila Ohno-Machado
Journal:  IEEE Trans Knowl Data Eng       Date:  2020-04-22       Impact factor: 9.235

4.  The trade-off between costs and outcomes: the case of acute myocardial infarction.

Authors:  Jonas Schreyögg; Tom Stargardt
Journal:  Health Serv Res       Date:  2010-09-01       Impact factor: 3.402

5.  Bayesian Stacked Parametric Survival with Frailty Components and Interval-Censored Failure Times: An Application to Food Allergy Risk.

Authors:  Matthew W Wheeler; Joost Westerhout; Joe L Baumert; Benjamin C Remington
Journal:  Risk Anal       Date:  2020-10-16       Impact factor: 4.302

6.  A multilevel model to estimate the within- and the between-center components of the exposure/disease association in the EPIC study.

Authors:  Francesco Sera; Pietro Ferrari
Journal:  PLoS One       Date:  2015-03-18       Impact factor: 3.240

Review 7.  Get real in individual participant data (IPD) meta-analysis: a review of the methodology.

Authors:  Thomas P A Debray; Karel G M Moons; Gert van Valkenhoef; Orestis Efthimiou; Noemi Hummel; Rolf H H Groenwold; Johannes B Reitsma
Journal:  Res Synth Methods       Date:  2015-08-19       Impact factor: 5.273

Review 8.  Survival analysis part IV: further concepts and methods in survival analysis.

Authors:  T G Clark; M J Bradburn; S B Love; D G Altman
Journal:  Br J Cancer       Date:  2003-09-01       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.